Ranbaxy Ills Lead To Fears Among Other Indian Drug Makers
This article was originally published in PharmAsia News
Executive Summary
The allegations Ranbaxy Laboratories exported contaminated pharmaceuticals to the United States has brought increased scrutiny of all Indian drug makers by the U.S. FDA. Several of the dozen or more companies that supply drug ingredients to U.S. and European drug makers are concerned the suspicions will bring greater oversight by the drug makers themselves, delaying approvals and shipment clearances. The firms also are concerned about increased costs and added regulatory hurdles hampering their work. The CEO of Neuland said recent communications indicate the U.S. FDA and other U.S. agencies plan more stringent actions to ensure quality compliance and greater disclosure. (Click here for more
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.